Silo Pharma (SILO) announced am update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously.
The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia. The launch of our non-GLP study in December 2024 marked the ...
The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia. The launch of our non-GLP study in December 2024 marked the first ...
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback